The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM).
Henry S. Friedman
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Annick Desjardins
Consultant or Advisory Role - Roche/Genentech
Katherine B. Peters
No relevant relationships to disclose
David A. Reardon
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
John Kirkpatrick
No relevant relationships to disclose
James Emmett Herndon
No relevant relationships to disclose
April D. Coan
No relevant relationships to disclose
Leighann Bailey
No relevant relationships to disclose
John Howard Sampson
No relevant relationships to disclose
Allan H. Friedman
No relevant relationships to disclose
James J Vredenburgh
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech